Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this trial is to evaluate the safety and efficacy of the non ergot dopamine agonist pramipexole for the treatment of tics in children and adolescents (age 6-17 years inclusive) diagnosed with Tourette Disorder according to DSM-IV criteria. The primary efficacy measure will be the Total Tic Score (TTS) of the YGTSS at 6 weeks.
Critère d'inclusion
- Tourette's syndrome